>>SANTA CLARA, Calif., Sept. 10 /PRNewswire/ -- Affymetrix, Inc., (Nasdaq: AFFX - news) announced today that GlaxoSmithKline plc (GSK) (NYSE: GSK - news) and Affymetrix expanded their agreement for Affymetrix' GeneChip® technology. GSK is a pioneer in applying genomics to pharmaceutical R&D. The agreement enables global GSK research sites to design custom GeneChip arrays on smaller format sizes that will provide them with lower cost arrays for use in high throughput settings. The high volume custom array access program is a flexible new offering from Affymetrix that provides specialized content on arrays at low prices.
``GSK's broader adoption of Affymetrix' GeneChip technology validates our belief that the market is shifting towards pre-synthesized oligonucleotide arrays,'' commented Susan E. Siegel, President of Affymetrix. ``By leveraging our unique and flexible wafer-based manufacturing process, we are able to provide chips at the lowest cost per datapoint in the industry with content intended to meet specific needs.''
``Affymetrix' GeneChip technology is a robust and critical complement to our internal microarray platform. Transcriptome analysis has been and remains one of the key components of our genomics tool box that we utilize for target identification and validation as well as disease understanding and compound progression,'' said Christine Debouck, Ph.D., Vice President, Worldwide Genomics of GSK.<<
snip
Cheers, Tuck |
